Source: Virtual Congress 2020 – Monoclonal antibodies; randomised controlled trials and real-world studies in asthma
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
S. LAURET (Toulouse, France), L. Guilleminault (Toulouse, France), E. Noel-Savina (Toulouse, France), G. Prevot (Toulouse, France), D. Brouquieres (Toulouse, France), A. Didier (Toulouse, France). Are serum immunoglobulins a predictive biomarker of response for anti-IL5 therapies?. 2266

Member's Comments

No comment yet.

Related content which might interest you: The serum YKL-40 is a useful biomarker for asthma Source: International Congress 2017 – Techniques to treat asthma Year: 2017 Is there any clinical application for determining the serum cytokines profile in sarcoid patients? Source: Annual Congress 2008 - Clinical aspects in the management of sarcoidosis Year: 2008 Can YKL-40 be used as a biomarker and therapeutic target for adult asthma? Source: Eur Respir J, 51 (1) 1702194; 10.1183/13993003.02194-2017 Year: 2018 Circulating total leptin as a diagnostic and prognostic biomarker in sepsis Source: International Congress 2019 – ECMO, ECCO2R and other rescue therapies in acute respiratory failure Year: 2019 The evaluation of serum biomarkers in patients with sarcoidosis: Can visfatin be a new biomarker for sarcoidosis? Source: International Congress 2017 – Rare diseases Year: 2017 Serum cytokine and antiviral antibody in the clinical course of sarcoidosis Source: Eur Respir J 2003; 22: Suppl. 45, 46s Year: 2003 Relationship between pre-treatment specific IgE and the response to omalizumab therapy Source: Annual Congress 2008 - Improving asthma and anti-allergic therapy Year: 2008 Serum KL-6 as a biomarker to assess risk of worse outcome in patients with SARS-CoV2 infection Source: Virtual Congress 2021 – COVID - 19 biomarkers Year: 2021 Free serum IgE suppression with omalizumab and clinical outcomes in asthma Source: International Congress 2019 – Clinical studies of asthma treatments Year: 2019 Immunoproteasome function as a potential biomarker for asthma severity and response to therapy Source: Virtual Congress 2021 – Emerging new mechanisms of chronic lung disease Year: 2021 Free plasmatic circulating DNA as prognostic and diagnostic lung cancer biomarker Source: Annual Congress 2008 - Novel trends in functional genomics and molecular pathology of neoplastic and non-neoplastic lung diseases Year: 2008 Clinical significance of serum MRGPRX2 as a new biomarker in allergic asthma Source: International Congress 2019 – Research and innovation in airway diseases Year: 2019 Serum eosinophil cationic protein as a potential biomarker for interleukin-5 antibody treatment in patients with severe uncontrolled eosinophilic asthma Source: International Congress 2018 – Biomarkers for evaluating asthma Year: 2018 Predictive biomarker of immune checkpoint inhibitors efficacy Source: New biomarkers, molecules and therapeutic sequences for non small cell lung carcinoma in the era of precision medicine Year: 2019 Altered Fc galactosylation in IgG4 is a potential serum marker for chronic lung disease Source: ERJ Open Res, 4 (3) 00033-2018; 10.1183/23120541.00033-2018 Year: 2018 Change in serum surfactant protein (SP)-A, SP-D and KL-6 predict the therapeutic effect of antifibrotic drugs in IPF. Source: International Congress 2019 – Biomarkers of idiopathic interstitial pneumonia Year: 2019 KL-6 is a useful serum biomarker for early detection of interstitial lung disease Source: Annual Congress 2012 - Diffuse parenchymal lung disease pathogenesis, biomarkers, therapy and new entities Year: 2012 Elevation of circulating endothelial cell levels in lung cancer – a new prognostic and/or predictive marker? Source: Annual Congress 2008 - Diagnosis and prognosis in thoracic oncology Year: 2008